Total Payments
$196,022
2024 Payments
$46,167
Companies
9
Transactions
72
Medicare Patients
3,698
Medicare Billing
$212,304
Payment Breakdown by Category
Research$115,240 (58.8%)
Consulting$52,979 (27.0%)
Other$25,366 (12.9%)
Travel$1,296 (0.7%)
Food & Beverage$1,141 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $115,240 | 3 | 58.8% |
| Consulting Fee | $52,979 | 38 | 27.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,366 | 10 | 12.9% |
| Travel and Lodging | $1,296 | 5 | 0.7% |
| Food and Beverage | $1,141 | 16 | 0.6% |
Payments by Type
Research
$115,240
3 transactions
General
$80,782
69 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $135,791 | 26 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $52,269 | 27 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $4,125 | 2 | $0 (2022) |
| BioMarin Pharmaceutical Inc. | $1,800 | 2 | $0 (2024) |
| Siemens Medical Solutions USA, Inc. | $760.40 | 9 | $0 (2024) |
| Abbott Laboratories | $760.00 | 2 | $0 (2017) |
| Celgene Corporation | $300.00 | 1 | $0 (2022) |
| VERTEX PHARMACEUTICALS INCORPORATED | $180.00 | 1 | $0 (2019) |
| Amgen Inc. | $36.58 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $46,167 | 15 | Eli Lilly and Company ($44,201) |
| 2023 | $89,782 | 13 | Eli Lilly and Company ($75,930) |
| 2022 | $33,275 | 20 | E.R. Squibb & Sons, L.L.C. ($19,779) |
| 2021 | $24,638 | 13 | E.R. Squibb & Sons, L.L.C. ($18,638) |
| 2020 | $735.08 | 2 | Eli Lilly and Company ($600.00) |
| 2019 | $408.85 | 3 | Siemens Medical Solutions USA, Inc. ($228.85) |
| 2018 | $36.58 | 2 | Amgen Inc. ($36.58) |
| 2017 | $979.34 | 4 | Abbott Laboratories ($760.00) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| 11/15/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| 10/28/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 10/04/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 09/23/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| 09/23/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 08/21/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $301.00 | General |
| 07/22/2024 | Siemens Medical Solutions USA, Inc. | NAEOTOM Alpha (Device), Biograph Vision 600 (8 Ring/64 CT), MAGNETOM Free.Max | Food and Beverage | In-kind items and services | $49.19 | General |
| Category: CT and RO incl. Computed Tomography and Radiation Oncology | ||||||
| 07/18/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 07/10/2024 | Siemens Medical Solutions USA, Inc. | NAEOTOM Alpha (Device), MAGNETOM Free.Max, Biograph Vision 600 (8 Ring/64 CT) | Food and Beverage | In-kind items and services | $90.90 | General |
| Category: CT and RO incl. Computed Tomography and Radiation Oncology | ||||||
| 07/02/2024 | Siemens Medical Solutions USA, Inc. | NAEOTOM Alpha (Device), MAGNETOM Free.Max, Biograph Vision 600 (8 Ring/64 CT) | Food and Beverage | In-kind items and services | $25.64 | General |
| Category: CT and RO incl. Computed Tomography and Radiation Oncology | ||||||
| 04/15/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 02/08/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $36,550.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT | ||||||
| 01/26/2024 | BioMarin Pharmaceutical Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| 01/26/2024 | BioMarin Pharmaceutical Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $225.00 | General |
| 11/01/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 08/07/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 05/24/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $134.70 | General |
| 05/16/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $6,975.00 | General |
| 05/05/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $18.50 | General |
| Category: Cardiovascular | ||||||
| 05/04/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $504.72 | General |
| 05/04/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $346.09 | General |
| 03/08/2023 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,916.00 | General |
| 03/01/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 02/23/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT | Eli Lilly and Company | $73,530 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT | Eli Lilly and Company | $41,710 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 874 | 913 | $197,980 | $49,927 |
| 2022 | 12 | 985 | 1,063 | $215,155 | $55,199 |
| 2021 | 11 | 989 | 1,071 | $204,882 | $55,993 |
| 2020 | 13 | 850 | 935 | $179,798 | $51,185 |
Total Patients
3,698
Total Services
3,982
Medicare Billing
$212,304
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 239 | 245 | $42,875 | $12,373 | 28.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 171 | 172 | $30,100 | $8,311 | 27.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 77 | 85 | $27,958 | $5,412 | 19.4% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Facility | 2023 | 57 | 57 | $18,696 | $5,091 | 27.2% |
| 75561 | Mri scan of heart before and after contrast | Facility | 2023 | 44 | 44 | $15,286 | $4,308 | 28.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 35 | 59 | $11,977 | $3,711 | 31.0% |
| 75572 | Ct scan of heart structure with contrast | Facility | 2023 | 58 | 58 | $13,978 | $3,645 | 26.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 19 | $10,773 | $2,516 | 23.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $6,412 | $1,269 | 19.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $4,257 | $1,137 | 26.7% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 13 | 13 | $4,550 | $1,095 | 24.1% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 38 | 38 | $2,584 | $689.85 | 26.7% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 48 | 48 | $2,784 | $253.80 | 9.1% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 50 | 50 | $5,750 | $114.68 | 2.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 322 | 329 | $57,575 | $16,885 | 29.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 137 | 137 | $23,975 | $6,532 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 86 | 99 | $29,648 | $6,181 | 20.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 51 | 108 | $21,690 | $6,106 | 28.1% |
| 75561 | Mri scan of heart before and after contrast | Facility | 2022 | 50 | 50 | $17,650 | $4,964 | 28.1% |
| 75572 | Ct scan of heart structure with contrast | Facility | 2022 | 79 | 79 | $19,039 | $4,510 | 23.7% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Facility | 2022 | 41 | 41 | $13,448 | $3,593 | 26.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 18 | $10,102 | $2,735 | 27.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 20 | 20 | $7,674 | $2,162 | 28.2% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2022 | 53 | 54 | $3,672 | $992.81 | 27.0% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2022 | 54 | 54 | $3,132 | $284.89 | 9.1% |
About Dr. Christopher Kramer, MD
Dr. Christopher Kramer, MD is a Cardiovascular Disease healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528137148.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Kramer, MD has received a total of $196,022 in payments from pharmaceutical and medical device companies, with $46,167 received in 2024. These payments were reported across 72 transactions from 9 companies. The most common payment nature is "" ($115,240).
As a Medicare-enrolled provider, Kramer has provided services to 3,698 Medicare beneficiaries, totaling 3,982 services with total Medicare billing of $212,304. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Charlottesville, VA
- Active Since 11/07/2006
- Last Updated 03/02/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1528137148
Products in Payments
- CRM-Research only (Device) $760.00
- NAEOTOM Alpha (Device) $196.98
- Gadavist (Drug) $124.86
- Biograph mMR (Device) $109.87
- ARTIS icono biplane (Device) $105.01
- Non-Product Specific (Device) $94.48
- Repatha (Biological) $36.58
- CAMZYOS (Drug) $18.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Charlottesville
Dr. Todd Villines, M.d, M.D
Cardiovascular Disease — Payments: $359,051
Cardiovascular Disease $359,051
David Lim
Cardiovascular Disease — Payments: $284,770
Cardiovascular Disease $284,770
Dr. Antonio Abbate, M.d, M.D
Cardiovascular Disease — Payments: $185,293
Cardiovascular Disease $185,293
Dr. Michael Ayers, M.d, M.D
Cardiovascular Disease — Payments: $172,824
Cardiovascular Disease $172,824
John Dimarco, M.d, M.D
Cardiovascular Disease — Payments: $108,809
Cardiovascular Disease $108,809
Pamela Mason, M.d, M.D
Cardiovascular Disease — Payments: $90,849
Cardiovascular Disease $90,849